Delving into the Latest Updates on Jiedu Tongluo granules with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Depressive Disorder

Originator Organization

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Active Organization-

Inactive Organization

Xiyuan Hospital of China Academy of Chinese Medical Sciences

License Organization-

Drug Highest PhasePendingEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Background: No comprehensive meta‐analysis has evaluated the efficacy and safety of the protective effect of Jiedu Tongluo Therapy on the kidney of DKD until now. This meta‐analysis covers this gap in knowledge.Methods: We have conducted an extensive search of databases, including CNKI, Wanfang, PubMed, and Web of Science. The selection was based on conventional treatment, including information and education on DKD, blood glucose, hypertension control methods, and lifestyle. The control group was composed of conventional western medicine or proprietary Chinese medicine, and the experimental group was composed of Jiedu Tongluo therapy controlled trials (RCTs) between 2003 and 2023. R 4.1.0 software was used to perform statistical analysis.Results: A total of 1871 patients from 19 RCTs were analyzed. Meta‐analysis results showed that the Jiedu Tongluo therapy was effective in improving clinical efficacy (OR = 2.47, 95% CI [1.94, 3.15], I2 = 0%), and these trials were more effective in reducing Scr (MD = −19.81, 95% CI [−27.64, −11.97], p < 0.01), BUN (MD = −0.70, 95% CI [−1.13, −0.27], p < 0.01), UAER (MD = −29.97, 95% CI [−37.33, −22.61], p < 0.01), FBG (MD = −0.85, 95% CI [−1.22, −0.47], p < 0.01), and certain medication safety (OR = 0.75, 95% CI [0.27, 2.11]).Conclusions: For treating diabetic kidney disease, TCM‐based Jiedu Tongluo therapy showed optimal clinical efficacy and safety. However, further rational experiments are needed to validate the above conclusions.

01 Dec 2018·TrialsQ4 · MEDICINE

The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: study protocol for a randomized controlled trial

Q4 · MEDICINE

ArticleOA

Author: Xu, Li ; Bilinksi, Kellie ; Liu, Jian-Xun ; Chang, Dennis ; Zhao, Ai-Mei ; Mao, Li-Jun ; Ren, Jun-Guo ; Yao, Ming-Jiang ; Qiu, Wen-Ran

BACKGROUNDPost-stroke depression (PSD) is the most common psychiatric complication after a stroke. The most frequently used antidepressants are selective serotonin receptor inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), however, these exhibit a series of side effects. Traditional Chinese medicine has been used to treat PSD with few side effects. The aim of this study is to evaluate the efficacy and safety of Jiedu Tongluo granules for treating PSD with qi deficiency and blood stasis syndrome.METHODSThe planned study is a double-blind, randomized, placebo-controlled pilot trial. Eighty participants will be randomly assigned to receive either treatment or placebo. The treatment group will receive Jiedu Tongluo granules (JDTLG) with conventional treatment, and the placebo group will receive placebo with conventional treatment for 8 weeks. The primary outcome is the effectiveness of JDTLG on depression after 8 weeks treatment, which is defined as a decrease of 50% or more in 17-item Hamilton Depression Scale (HAMD-17) score or clinical recovery (score < 7). Secondary outcomes are improvement in neurological function, degree of independence, activities of daily living, and TCM syndrome at each visit, which will be measured with National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI) and TCM scale, respectively. Interleukin (IL)-6, IL-8, and small-molecule metabolites will be monitored to explore the mechanism of action of JDTLG on PSD. Safety measures include vital signs, results of electrocardiography, laboratory index (full blood count, kidney and liver function tests) and adverse events.DISCUSSIONThe purpose of this trial is to evaluate the therapeutic effects and safety of JDTLG in individuals with PSD with concomitant qi deficiency and blood stasis syndrome. If successful, the outcome of this trial will provide a viable treatment option for PSD patients.TRIAL REGISTRATIONClinicalTrials.gov ID: NCT03147053 . Registered on 27 April 2017.

01 Mar 2014·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Protective effect of jiedu tongluo injection on cerebral edema in rats with lesion of cerebral ischemia/reperfusion].

Article

Author: Wu, Li-Fei ; Guan, Ya-Lan ; Zhang, Wen-Sheng ; Xing, Yue ; Liu, Zhen-Quan

OBJECTIVETo investigate the protective effects of Jiedu Tongluo injection on cerebral edema induced by focal lesion of cerebral ischemia/reperfusion, the hydrous content of brain and the expressions of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin and MMP-9 in rats.METHODThe model of brain middle cerebral artery ischemia/reperfusion was established by the thread approach. After 24 hours of reperfusion, cerebral edema formation was determined by the hydrous content of brain. The permeability of blood brain barrier was evaluated based on the leakage of Evans blue. Enzyme-linked immunoadsordent assay (ELISA)was used to examine the expression of ICAM-1, VCAM-1, E-selectin. The expression of MMP-9 was measured by immunohistochemistry.RESULTJDTL, in the dose of 2 mL x kg(-1) and 4 mL x kg(-1), relieved cerebral edema (P < 0.05, P < 0.01), reduced the expressions of ICAM-1, VCAM-land E-selectin and decreased MMP-9 activity (P < 0. 05, P < 0.01) in model rats.CONCLUSIONJiedu Tongluo injection has a protective effect on rat brain from cerebral edema induced by the injury of focal cerebral ischemia/reperfusion. The mechanism is related to that Jiedu Tongluo injection can reduce the expressions of ICAM-1, VCAM-1 and E-selectin and inhibit of MMP-9 activation in rat brain.

100 Deals associated with Jiedu Tongluo granules

Login to view more data